Bio-Rad Laboratories Geenius System Assays and Controls

Background

The Florida Department of Health (FDOH) Bureau of Public Health Laboratories (BPHL) is seeking to purchase a confirmatory assay system for HIV testing. This system is essential for performing HIV-1/HIV-2 Supplemental differentiation assay testing to confirm HIV infection in patients who have tested positive on initial screenings. The purchase is justified as a single source acquisition due to the unique capabilities of the Bio-Rad Laboratories Geenius™ System, which is the only FDA approved differential assay currently available in the U.S.

Work Details

The contract involves the procurement of the Bio-Rad Laboratories Geenius™ System assays and controls necessary for conducting HIV-1/HIV-2 Supplemental differentiation testing and Newborn Screening Sickle Cell tests. The assays must be capable of testing whole blood, serum, plasma, and in-house validated oral fluid in accordance with CDC 2014 HIV Diagnostic Algorithm guidelines. The specific commodities required fall under the following categories:

12161500 Indicators and Reagents

- 41116000 Clinical and diagnostic analyzer reagents - 41116100 Manual test kits and quality controls.

Period of Performance

The contract will be executed over a term of three years.

Place of Performance

The performance will take place at the Florida Department of Health facilities as specified by the Bureau of Public Health Laboratories.

Bidder Requirements

This procurement is designated as a single source purchase from Bio-Rad Laboratories, Inc., which is the sole distributor of the Geenius™ System. There are no stated set-aside certifications or additional requirements specified for bidders.